Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia

NCT07584057 is registered in ClinicalTrials.gov with Yunnan Baiyao Group Co., Ltd. as lead sponsor.

NCT NCT07584057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07584057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia
Lead sponsor
Yunnan Baiyao Group Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
March 31, 2030
Enrollment
146 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer cachexia